We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Doximity (DOCS) Falls More Steeply Than Broader Market: What Investors Need to Know
Read MoreHide Full Article
In the latest close session, Doximity (DOCS - Free Report) was down 1.3% at $24.39. This change lagged the S&P 500's 0.24% loss on the day. Elsewhere, the Dow lost 0.01%, while the tech-heavy Nasdaq lost 0.26%.
Heading into today, shares of the medical social networking site had gained 1.23% over the past month, outpacing the Medical sector's loss of 0.68% and lagging the S&P 500's gain of 6.42%.
Market participants will be closely following the financial results of Doximity in its upcoming release. It is anticipated that the company will report an EPS of $0.28, marking a 26.32% fall compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $143.67 million, up 3.89% from the year-ago period.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $1.54 per share and revenue of $643.12 million, indicating changes of +8.45% and +12.75%, respectively, compared to the previous year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Doximity. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. At present, Doximity boasts a Zacks Rank of #4 (Sell).
Looking at valuation, Doximity is presently trading at a Forward P/E ratio of 15.57. This represents a discount compared to its industry average Forward P/E of 22.46.
Also, we should mention that DOCS has a PEG ratio of 1.23. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Medical Info Systems stocks are, on average, holding a PEG ratio of 1.37 based on yesterday's closing prices.
The Medical Info Systems industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 85, placing it within the top 35% of over 250 industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Doximity (DOCS) Falls More Steeply Than Broader Market: What Investors Need to Know
In the latest close session, Doximity (DOCS - Free Report) was down 1.3% at $24.39. This change lagged the S&P 500's 0.24% loss on the day. Elsewhere, the Dow lost 0.01%, while the tech-heavy Nasdaq lost 0.26%.
Heading into today, shares of the medical social networking site had gained 1.23% over the past month, outpacing the Medical sector's loss of 0.68% and lagging the S&P 500's gain of 6.42%.
Market participants will be closely following the financial results of Doximity in its upcoming release. It is anticipated that the company will report an EPS of $0.28, marking a 26.32% fall compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $143.67 million, up 3.89% from the year-ago period.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $1.54 per share and revenue of $643.12 million, indicating changes of +8.45% and +12.75%, respectively, compared to the previous year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Doximity. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. At present, Doximity boasts a Zacks Rank of #4 (Sell).
Looking at valuation, Doximity is presently trading at a Forward P/E ratio of 15.57. This represents a discount compared to its industry average Forward P/E of 22.46.
Also, we should mention that DOCS has a PEG ratio of 1.23. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Medical Info Systems stocks are, on average, holding a PEG ratio of 1.37 based on yesterday's closing prices.
The Medical Info Systems industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 85, placing it within the top 35% of over 250 industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.